TEM
"Tempus AI grew revenue 83% to $1.27B but only 2% came from AI applications. Is the data moat worth an AI-sector premium, or has the rebrand inflated expectations beyond what the diagnostic business can deliver?"
Tempus AI is a precision medicine company operating CLIA-certified genomic sequencing labs and a proprietary multimodal data platform spanning 450+ petabytes and 500K+ patient records. The company rebranded from Tempus Labs before its June 2024 IPO, drawing a Spruce Point Capital short report alleging AI-washing and TCV inflation. Revenue grew 83% in FY2025 (though ~50% from the Ambry Genetics acquisition), and the company guided to $1.59B in FY2026 with $65M adjusted EBITDA.
Executive Summary
Cross-lens roll-up assessment
Tempus AI presents a paradox: genuinely strong operational momentum in genomic diagnostics and data licensing, underpinned by a unique multimodal data asset, wrapped in an AI narrative that systematically overstates the company's current AI revenue contribution. The committee found the data moat DEFENSIBLE, revenue growth CONDITIONAL on regulatory execution, and governance structures MISALIGNED due to dual-class control combined with systematic insider selling. The core business merits attention; the valuation premium merits skepticism.
TEM warrants HIGHER_SCRUTINY rather than PROCEED_WITH_CAUTION because governance concerns (dual-class structure, related-party TCV, systematic insider selling) create information asymmetry, and the AI narrative premium means downside is amplified if the market re-rates to diagnostics multiples. The underlying business has genuine strengths (data moat, 33% organic growth, positive EBITDA inflection), but the gap between operational reality and market positioning requires ongoing verification. De-escalation triggers: first meaningful AI algorithm revenue, ASP reaching $2,000+, CEO selling pace reduction. Escalation triggers: TCV non-binding opt-in percentage rising, securities class action surviving motion to dismiss, organic growth decelerating below 25%.
Key Takeaways
- •ACCOUNTING_INTEGRITY is QUESTIONABLE: Total Contract Value of >$1.1B includes $300M in non-binding opt-ins and a $200M Pathos deal involving entities controlled by company leadership, inflating the metric that management uses to signal demand visibility.
- •REVENUE_DURABILITY is CONDITIONAL: Core organic growth of ~33% is healthy, but headline 83% growth includes the Ambry acquisition. ASPs ($1,640) sit $500+ below peer levels and target of $2,200+, creating dependency on FDA clearance pathway execution for margin expansion.
- •NARRATIVE_REALITY_GAP is DIVERGING: Only 2% of FY2024 revenue came from AI applications despite the 'Tempus AI' rebrand. Foundation model investment is real (1,000+ H200 GPUs, AstraZeneca partnership) but produces zero revenue. The AI premium in the stock may not survive sustained scrutiny.
- •COMPETITIVE_POSITION is DEFENSIBLE: The 450-petabyte multimodal data repository with 500K+ patient records, 5,500+ hospital connections, and 8,500+ ordering oncologists creates genuine switching costs that would take competitors 5-10 years to replicate.
- •GOVERNANCE_ALIGNMENT is MISALIGNED: Dual-class share structure gives CEO Lefkofsky voting control while he sells 775K+ shares via 10b5-1 plans. The Groupon co-founder parallel, while imperfect, adds pattern recognition to the governance concern.
- •REGULATORY_EXPOSURE is ELEVATED: FDA clearance pathway for xT CDx, xF, and xR is the single largest margin lever. Securities class action pending from AI-washing allegations. MRD reimbursement at MolDX could unlock significant growth optionality.
Key Tensions
- •The data moat is real but the AI narrative inflates its perceived value: Tempus's competitive advantage is in proprietary clinical data and lab infrastructure, yet the stock trades at AI multiples (~7x revenue) rather than diagnostics multiples (3-4x). A narrative correction could compress the multiple even as the business executes well.
- •Revenue growth is strong but overstated: The gap between 83% headline growth and ~33% organic growth creates an expectations management challenge as Ambry contributions annualize.
- •CEO selling conflicts with promotional tone: Lefkofsky publicly describes Tempus as 'poised for a phenomenal 2026' while systematically reducing his economic exposure. Both statements could be simultaneously true, but the divergence warrants monitoring.
Fugazi Filter
Are the numbers trustworthy?
Dual-Axis Risk Classification
Position shows Accounting Integrity × Funding Fragility
No elevated red flags detected. Standard investment analysis practices apply — focus on valuation and business fundamentals.
Key FindingsClick to expand details
Signal AssessmentsClick for full context
| Signal | Scale | Assessment | Evidence |
|---|---|---|---|
Accounting Integrity | — | QUESTIONABLE | 2Corroborated |
Governance Alignment | — | MISALIGNED | 2Corroborated |
Model Debates
Cross-Lens Insights
Where Lenses Agree
- Governance-Narrative Alignment Concern
- Revenue Growth Is Real but Systematically Overstated
- FDA Regulatory Pathway Is the Primary Value Driver
- Data Moat Is Genuine but AI Premium May Be Unearned
Where Lenses Differ
GOVERNANCE_ALIGNMENT
Fugazi Filter weighted structural governance issues (dual-class, related-party deals) more heavily, while Insider Investigator focused narrowly on insider trading patterns and acknowledged early post-IPO diversification as mitigating.
The following publicly available documents were collected and extracted into a structured fact dossier that powered this analysis.
SEC Filing
- Annual Report (10-K) — FY2025
- Quarterly Report (10-Q) — Q3 2025
- Quarterly Report (10-Q) — Q2 2025
- Quarterly Report (10-Q) — Q1 2025
- Quarterly Report (10-Q) — Q3 2024
- Current Reports (8-K) — 10 filings (2025-2026)
- Proxy Filing (DEFA14A) — April 2025
- Form 4 Insider Transaction Filings — 20 filings
Earnings Transcript
- Q4 2025 Earnings Call Transcript
- Q3 2025 Earnings Call Transcript
- Q2 2025 Earnings Call Transcript
- Q1 2025 Earnings Call Transcript
Research Document
- Spruce Point Capital — Strong Sell Report on Tempus AI (May 2025)